No easy road to outsmart cancer
Hopes of greatly speeding up the evaluation of new therapies by using tumour response to a short course of neoadjuvant treatment as a surrogate for clinical benefit have proved false and the sooner we recognise [more]
multi gene assays
Reading the signs
The concept of a genomic signature that can define any tumour according to its unique biology has been central to the emerging paradigm of personalised therapy. But how helpful are multi-gene assays in guiding treatment [more]